Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Empagliflozin in Patients with Chronic Kidney Disease.

Journal article

EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Journal article

Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845

Focused cardiac ultrasound to guide the diagnosis of heart failure in pregnant women in India.

Journal article

Alsharqi M. et al, (2022), J Am Soc Echocardiogr

Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.

Journal article

Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.

Journal article

EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis.

Journal article

Task Force for the management of COVID-19 of the European Society of Cardiology None. et al, (2022), Cardiovascular research, 118, 1385 - 1412

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

Journal article

HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), Eur Heart J, 43, 1416 - 1424

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.

Journal article

Task Force for the management of COVID-19 of the European Society of Cardiology None., (2022), European heart journal, 43, 1059 - 1103

European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis.

Journal article

Task Force for the management of COVID-19 of the European Society of Cardiology None., (2022), European heart journal, 43, 1033 - 1058

CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA

Presentation

Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16

A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts

Presentation

Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3149 - 3149

Load More